Bath emollients among further prescribing restrictions issued by NHS England

GPs should no longer routinely prescribe bath and shower emollients, among other items of low cost-effectiveness, NHS England has said.

Primary care prescribers should not initiate emollient bath and shower preparations for any new eczema patient. | GETTY IMAGES
Primary care prescribers should not initiate emollient bath and shower preparations for any new eczema patient. | GETTY IMAGES

Following the restrictions issued last year on prescribing of 35 'low-priority' treatments, NHS England has identified seven more items that should not routinely be prescribed in primary care. They are:

Further information

NHS England guidance

Emollient bath additives were shown in the randomised controlled BATHE trial to have no clinical benefit in childhood eczema, and NHS England has ruled that this finding can be extrapolated to adults in the absence of other good-quality evidence. 'Leave-on' emollients remain the mainstay of treatment for eczema and can be used as soap substitutes if necessary.

Insulin pen needles that cost more than £5 per 100 needles should not be initiated for any diabetes patient in primary care. A 4mm needle is considered to be the safest option for adults and children regardless of age, gender and BMI, as shorter needles help to prevent intramuscular injection of insulin. For patients currently using longer needles (8mm or 12mm), it is advisable to change to a shorter needle after discussion with a healthcare professional.

Minocycline is not recommended for use in acne as it is associated with an increased risk of adverse effects such as drug-induced lupus, skin pigmentation and hepatitis. Aliskiren, amiodarone and dronedarone are not recommended by NICE for routine prescribing.

NHS England estimates that implementation of the new restrictions could save up to £22.4 million.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...